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Abstract: Cardiac tissue engineering is very much in a current focus of regenerative medicine
research as it represents a promising strategy for cardiac disease modelling, cardiotoxicity testing and
cardiovascular repair. Advances in this field over the last two decades have enabled the generation
of human engineered cardiac tissue constructs with progressively increased functional capabilities.
However, reproducing tissue-like properties is still a pending issue, as constructs generated to date
remain immature relative to native adult heart. Moreover, there is a high degree of heterogeneity in
the methodologies used to assess the functionality and cardiac maturation state of engineered cardiac
tissue constructs, which further complicates the comparison of constructs generated in different
ways. Here, we present an overview of the general approaches developed to generate functional
cardiac tissues, discussing the different cell sources, biomaterials, and types of engineering strategies
utilized to date. Moreover, we discuss the main functional assays used to evaluate the cardiac
maturation state of the constructs, both at the cellular and the tissue levels. We trust that researchers
interested in developing engineered cardiac tissue constructs will find the information reviewed here
useful. Furthermore, we believe that providing a unified framework for comparison will further the
development of human engineered cardiac tissue constructs displaying the specific properties best
suited for each particular application.
Keywords: pluripotent stem cells; cardiomyocytes; cardiac tissue engineering; human heart;
tissue maturation
1. Introduction
Cardiovascular diseases (CVD) remain the main cause of morbidity and mortality world-
wide despite many advances in preventive cardiology. According to 2017 estimates, CVD
accounted for over 420 million cases every year and resulted in close to 18 million deaths [1].
Acute myocardial infarction (MI) and subsequent heart failure continue to have high prevalence
worldwide [2] and are among the major health issues. As the human adult heart has minimal
regenerative capacity [3], cardiomyocytes (CMs) that are lost during ischemic injuries are usually
replaced with fibrotic scar tissue leading to the partial or total cardiac dysfunction [4]. Today
the only curative option for patients with end-stage heart failure is heart transplantation, which
is usually limited due to the scarcity of donor hearts [5]. Preclinical research studies have
demonstrated that cell therapy can attenuate myocardial damage and reduce the progression of
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cardiac remodeling to heart failure [6]. However, clinical studies have failed to show significant
improvements and preliminary data indicate that stem cells have the potential to enhance
tissue perfusion and contractile performance [7]. Numerous studies have demonstrated that
the therapeutic benefits exerted by cells are mainly attributable to the release of complementary
paracrine factors and the efficacy is limited as only a small percentage of transplanted cells
engrafted in the infarcted tissue [8]. Studies on animal models showed that combining cell
therapy with tissue engineering techniques for the creation of cell sheets and patches, can
increase stem cell survival and boost therapeutic action [9]. Therefore, tissue engineering has
been considered as a potential approach for cardiac regeneration after MI. Current research
in the field is, to a large extent, aimed towards the development of functional heart tissue for
application in cell-based regenerative therapies [10,11], cardiac disease modeling [12–15] and
drug screening [16]. In particular, the application of cardiac tissue engineering (CTE) systems for
investigating mechanisms of disease has been recently reviewed [17] and will not be specifically
covered here. Despite the evident progress realized to date, engineered cardiac tissues (ECT)
remain immature and still differ from the adult human heart. One of the major challenges in
CTE is the organization of stem-cell derived CMs into a functional tissue of large dimensions
suitable for the intended therapeutic use, and that recapitulates the main physiological prop-
erties of the real heart. In this review, we describe the main approaches undertaken toward
the development of ECT constructs, along with the methodologies utilized for assessing their
functionality, and discuss the current state and future directions.
2. Cell Sources
The heart muscle is composed of electrically and mechanically connected CMs closely
surrounded by endothelial cells (ECs), fibroblasts (FBs), smooth muscle cells (SMCs), pericytes,
and heart resident immune cells [18]. Even though CMs constitute approximately 70–85%
of the heart by volume [19], non-myocyte cells are more abundant by cell number and
bear critical roles in heart homeostasis, supporting the extracellular matrix, intercellular
communication, and vascular supply essential for CM survival and contraction [19,20]. Thus,
the most advanced current CTE approaches aim at generating 3-dimensional (3D) constructs
that incorporate CMs as well as non-myocyte cardiac cells to reproduce the myocardial niche
and allow the creation of a functional mature structure (Figure 1 and Table 1).
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Figure 1. Main types of cell sources, cardiac constructs and mat ration ethods used in CTE. The cell types most frequently
used as source for CTE include neonatal rodent cardiomyocytes, ESC-or iPSC-derived endothelial cells, cardiomyocytes
and fibroblasts, and mesenchymal stromal cells derived from bone marrow or adipose tissue. Different systems have
been developed to generate ECT including cell sheets, scaffolds, hydrogels, bundles, spheroids, heart-on-a-chip, and
3D-bioprinted constructs. The main methods used to increase maturation of cardiac constructs comprise mechanical and/or
electrical stimulation, co-culturing with non-myocyte cells and continuous perfusion within bioreactors. See main text for
details. Figure created with BioRender.com and smart.servier.com.
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Table 1. Representative studies on CTE.
CTE Construct Cell Source Culture Conditions Functional Analyses Ref.
Type Area(mm2)
Thickness
(mm) Species Cell Type Stimulation Perfusion Time (d) CM Maturation Tissue Maturation
Scaffold 70 2 Rat Neonatal CM No Yes 10 Protein expression No functional analyses [21]
Scaffold 95 1.5 Rat Neonatal CM No Yes 7 Protein expression Contractile activity [22]
Scaffold 48 1.5 Rat Neonatal CM Electrical stimulation No 8 Protein expression, sarcomere structure Contractile activity [23]
Scaffold 95 1.5 Rat Neonatal CM No Yes 14 No functional analyses Contractile activity [24]
Scaffold 48 1.5 Rat Neonatal CM Electrical stimulation No 8 Protein expression, sarcomere structure Contractile activity [25]
Scaffold 20 2 Rat Neonatal CM Electrical stimulation Yes 4 Protein expression No functional analyses [26]
Scaffold 50 1 Rat Neonatal CM Electrical stimulation Yes 8 No functional analyses Contractile activity [27]
Scaffold 20 2 Rat Neonatal CM Mechanical stimulation Yes 4 Protein expression No functional analyses [28]
Scaffold 80 5 Rat Neonatal CM No No 7 No functional analyses Calcium imaging [29]
Scaffold n/a n/a Human ESC-CM Mechanical stimulation No 14 Protein expression Force of contraction [30]
Scaffold 56 3.5 Human ESC-CM Mechanical No 5 Gene/Protein expression Calcium imaging [31]
Scaffold 80 1 Rat/human Neonatal CM/iPSC-CM Electrical stimulation Yes 14 Gene/protein expression,sarcomere structure
Force of contraction, contractile activity,
whole construct electrical activity [32]
Hydrogel n/a n/a Rat Neonatal CM Mechanical stimulation No 14 Protein expression, sarcomere structure,electrical signal propagation Force of contraction [33]
Hydrogel n/a 0.9 Rat Neonatal CM Mechanical stimulation Yes 14 Gene/protein expression Force of contraction [34]
Hydrogel n/a n/a Rat Neonatal CM Electro-mechanicalstimulation No 13 Protein expression Force of contraction, calcium imaging [35]
Hydrogel 60 n/a Human ESC-CM/iPSC-CM+HUVEC+MSC Mechanical stimulation No 4 Gene expression, sarcomere structure Force of contraction [36]
Hydrogel 0.4 n/a Human ESC-CM No No 14 Gene/protein expression, patch clamp Force of contraction [37]
Hydrogel n/a 0.1 Rat/human Neonatal CM/ESC-CM Electro-mechanicalstimulation No 7 Gene/protein expression Contractile activity, optical mapping [38]
Hydrogel 49 n/a Human ESC-CM No No 14 Gene/protein expression,sarcomere structure Force of contraction, optical mapping [39]
Hydrogel 3 0.3 Human iPSC-CM Electrical stimulation No 14 Protein expression, sarcomere structure,patch clamp
Contractile activity, optical mapping,
calcium imaging [40]
Hydrogel 15 n/a Rat/human Neonatal CM/ESC-CM Electrical stimulation Yes 14 Protein expression Force of contraction, contractile activity [41]
Hydrogel 5 n/a Human ESC-CM No No 24 Gene/protein expression,sarcomere structure Force of contraction, optical mapping [42]
Hydrogel n/a n/a Human iPSC-CM No No 7 Protein expression,electrical signal propagation No functional analyses [43]
Hydrogel 0.125 n/a Human iPSC-CM No No 15 Gene/protein expression No functional analyses [44]
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CTE Construct Cell Source Culture Conditions Functional Analyses Ref.
Hydrogel 27 0.2 Human iPSC-CM+iPSC-EC/HUVEC No No 15 Gene/Protein expression Optical mapping [45]
Hydrogel 4 n/a Human iPSC-CM No No 40 Protein expression, sarcomere structure Force of contraction [46]
Hydrogel 20 0.3 Human iPSC-CM Electro-mechanicalstimulation No 14 Protein expression, sarcomere structure Force of contraction, calcium imaging [47]
Hydrogel 14 0.2 Rat/human Neonatal CM/iPSC-CM No No 14 Gene/protein expression Force of contraction, optical mapping [48]
Hydrogel 200 n/a Human iPSC-CM No No 60 Protein expression,electrical signal propagation No functional analyses [49]
Hydrogel 900 n/a Human iPSC-CM No No 28 Protein expression Force of contraction, contractile activity [50]
Hydrogel 1190 0.5 Human ESC-CM/iPSC-CM Mechanical stimulation No 45 Gene expression, sarcomere structure,patch clamp Force of contraction [51]
Hydrogel 1296 0.1 Human iPSC-CM No No 21 Gene/protein expression,sarcomere structure Force of contraction, optical mapping [11]
Hydrogel 100 0.1 Rat/human Neonatal CM/ESC-CM Electrical stimulation No 7 No functional analyses Force of contraction, contractile activity [52]
Hydrogel 800 n/a Human iPSC-CM+iPSC-EC+iPS-SMC No No 7 Protein expression Force of contraction, optical mapping [53]
Hydrogel 5 0.3 Human ESC-CM/iPSC-CM+hcFB Electrical stimulation No 42 Gene/Protein expression, sarcomerestructure, patch clamp
Force of contraction, contractile activity,
calcium imaging [54]
Hydrogel 11 n/a Human iPSC-CM Electrical stimulation No 30 Gene/protein expression, sarcomerestructure, patch clamp Force of contraction, calcium imaging [55]
Hydrogel 14 2 Human/Pig/Rat iPSC-CM+iPSC-EC/NeonatalCM+HUVEC+FB No No 7 Gene/Protein expression Optical mapping, calcium imaging [56]
Cell sheets 116 0.045 Rat Neonatal CM No No 4 Protein expression, sarcomere structure,electrical signal propagation Force of contraction [57]
Cell sheets 960 0.1 Rat/human Neonatal CM+EC No Yes 10 Protein expression No functional analyses [58]
Cell sheets 70 0.1 Human iPSC-CM+MSC No No 4 Protein expression,electrical signal propagation Contractile activity [59]
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2.1. Neonatal Rodent Myocytes
The first studies on cardiac engineering in the late 1990s used cells derived from neona-
tal rat hearts since human CMs were not readily available and could not be expanded from
cardiac biopsies [60–62]. Moreover, while human embryonic stem cells (hESC) were first
derived in 1998, robust protocols to guide cardiac differentiation took another decade to be
perfected and yield human CMs with the desired purity and reproducibility [63–65]. On the
other hand, the use of adult ventricular myocytes from both rats and mice showed low via-
bility and proliferation rate in long-term cultures which made them useless for CTE [66,67].
Thus, by this period of time neonatal rat cardiac myocytes (NRCMs) became the preferred
cell source for CTE as they could be isolated with high yield and quality and presented
comparably long-term viability in culture. Therefore, NRCMs were used to generate 3D
functional cardiac tissue constructs in which cells underwent progressive electromechanical
maturation over time in static conditions [22,35,38,41,48,57,60,68] while culturing these 3D
constructs in dynamic systems further enhanced their functionality [24–26,28,34,41,69–72].
2.2. Pluripotent Stem Cells
Pluripotent stem cells (PSCs), including embryonic and induced pluripotent stem
cells (ESC and iPSCs), show promise for CTE as they can be expanded indefinitely in vitro
and differentiated into multiple cell types including CMs. Robust protocols have been
developed for cardiac differentiation of PSCs allowing to obtain high yield of CMs [63,73,74].
The therapeutic potential of both human ESC- and iPSCs-derived CMs has been previously
demonstrated in different animal models of MI including mice [75], rats [76–78], guinea
pigs [79], pigs [80], and non-human primates [81]. Remarkably, Shiba et al. demonstrated in
2016 that allogeneic transplantation of iPSC-CMs can regenerate the damaged heart in a non-
human primate MI model. The authors generated iPSCs from an animal homozygous for a
specific major histocompatibility complex haplotype (HT4), which were then differentiated
into CMs. A total of 4 × 108 iPSC-CMs were injected in the infarcted heart of HT4-
heterozygous primates. Cells survived and engrafted for at least 12 weeks with no evidence
of immune rejection. However, some grafts remained isolated from the host tissue and the
incidence of arrhythmias increased after cell transplantation, although the incidence was
transient and decreased gradually over time [82].
Transplantation of ECT constructs comprising human PSC-derived CMs has been
shown to enhance cell survival and engraftment, promote tissue revascularization and
improve functional properties of the injured heart. The Murry laboratory generated ECT
constructs using hESC-CMs or hiPSC-CMs together with human umbilical vein ECs, and
mesenchymal stromal cells (MSCs) in a type I collagen hydrogel and subjected them to
uniaxial mechanical loading [36]. One week after transplantation onto injured hearts of
athymic rats, the ECT constructs survived and formed grafts containing a microvascular
network that was perfused by the host coronary circulation. Kawamura et al. used the
cell sheet method to deliver hiPSC-CMs onto infarcted swine hearts. This procedure
significantly improved contractile function, promoted vascularization and attenuated left
ventricular remodeling. However, poor level of engraftment was detectable 8 weeks
post-transplantation [83]. Transplantation of ECT constructs from hESC-CMs in a chronic
rodent MI model has been shown to enhance engraftment rate, leading to increased long-
term survival, and progressive maturation of the human CMs [30]. Engineered tissues
containing hiPSC-derived vascular cells (ECs and SMCs) without CMs have also been
associated with significant functional improvement, reduction of infarct size, increase in
neovascularization, and recruitment of endogenous cardiac progenitor cells in a MI swine
model [84]. Cardiac repair has also been reported after implantation of ECT constructs
comprising hiPSC-derived cells in guinea pigs [45] and pigs [85].
Representative publications on CTE, indicating the sources and types of cells used, the
type and dimension of the constructs generated, the culture conditions, and the functional
analyses performed. CM, cardiomyocytes; iPSC-CM, cardiomyocytes derived from induced
pluripotent stem cells; ESC-CM, cardiomyocytes derived from embryonic stem cells; EC,
Int. J. Mol. Sci. 2021, 22, 1479 6 of 29
endothelial cells; HUVEC, human umbilical vein endothelial cells; FB, fibroblasts; hcFB,
human cardiac fibroblasts; SMC, smooth muscle cells; MSC, mesenchymal stromal cells;
n/a, information not available.
Notably, Menasché et al. reported the first clinical use of hESC-derived cardiovascular
progenitor cells in a fibrin patch of 20 cm2, which was delivered to the heart of a patient
suffering from severe ischemic left ventricular dysfunction. The study demonstrated the
feasibility of generating a clinical-grade population of hESC-derived cardiovascular pro-
genitors and improved the patient’s functional outcome after a 3-month follow-up [86]. In
a subsequent study, the group tested the safety of this approach on 6 patients with up to
one year follow-up, during which the patients did not present any clinically significant
arrhythmias and showed an increase in systolic function. One patient died after surgery
from treatment-unrelated comorbidities and another one at 22 months due to heart fail-
ure [87]. No tumors were detected during the follow-up period, demonstrating the safety
of this approach at 1 year.
2.3. Mesenchymal Stromal Cells
Mesenchymal stromal cells (MSCs) are multipotent cells that have the potential to
differentiate into a variety of cell types like adipocytes, chondrocytes and osteocytes,
limited self-renewal capacity, and low immunogenicity [88]. Despite the adipocyte tissue
and bone marrow being the most common sources for MSCs [89], they can be also isolated
from synovial tissue, umbilical cord and peripheral blood [90]. MSCs were considered in
autologous and allogeneic therapies for cardiac injuries due to their high expansion rate
and immunomodulatory properties. In particular, numerous preclinical trials have shown
that MSCs have the potential to promote cardiac repair in heart injury models through
paracrine effects [91–95]. Moreover, engineered constructs containing MSCs have also been
evaluated in preclinical models of MI. Patches consisting of autologous porcine MSCs in a
fibrin hydrogel were transplanted onto infarcted swine hearts and resulted in improvement
in contractile function and increase in neovascularization in the patch covered area [96].
Later, human MSCs cultured in a scaffold made of decellularized human myocardium
with fibrin hydrogel were transplanted in nude rat models of acute and chronic MI. The
treatments showed cardiac functional improvement 4 weeks after transplantation that was
associated with the release of proangiogenic factors by MSCs [97]. Moreover, researchers
have found an important structural role of MSCs for the organization of cardiac tissues. In
particular, co-culture of human MSCs with hPSC-derived CMs and vascular cells within
ECT constructs markedly improved their self-organization, vascular network formation
and stabilization [36,59]. Finally, cell heterogeneity in ECT constructs due to the presence
of MSCs has also been reported to influence successful engraftment [36] and to aid in the
generation of human in vitro disease models of high pathophysiological relevance [59].
2.4. Non-Myocytes
Within the native heart, CMs are never alone but rather organize in a complex 3D tis-
sue with intimately coupled non-myocyte cells. Moreover, heart homeostasis and response
to disease strongly depends on the interaction between non-myocytes and cardiomyocytes.
It therefore follows that recapitulating the normal heart tissue organization in the laboratory
would necessitate including CMs along with non-myocytes [3,98]. Liau et al. generated
two types of patches containing mouse ESC-derived CMs alone, or in combination with
different ranges of cardiac FBs (3%, 6% and 12%). Based on their results, patches containing
only ESC-CMs failed to form a functional syncytium, while the presence of cardiac FBs
allowed the generation of synchronously contractile constructs with functional properties
close to the native heart [99]. Building on those findings, Zhang et al. generated cardiac
patches using human ESC-derived CMs with varying purity (49–90%) together with car-
diac FBs, endothelial cells, and vascular SMCs, which inadvertently arose during cardiac
differentiation. Interestingly, the conduction velocity in patches linearly increased with
CMs purity, and when compared to matched 2D monolayers, 3D tissues showed higher
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conduction velocities but not different action potential duration or maximum capture rates.
Moreover, the authors found that inclusion of non-myocytes increased the survival and
the maturation level of CMs [100]. Tiburcy et al. also demonstrated the critical impor-
tance of defining the non-myocyte fraction for engineering force-generating cardiac tissues.
Specifically, these authors found that the ratio of 70% hPSC-derived CMs and 30% human
foreskin FBs was optimal for promoting maturation at the cellular and tissue levels [51].
Many subsequent studies have confirmed the significance of including non-myocytes in
engineered cardiac constructs [32,36,51,53,55,101–104].
3. Cardiac Tissue Engineering Systems
A wide variety of 3D ECT constructs with different shapes and sizes/thicknesses have
been fabricated with the purpose of being used as model systems for drug/toxicity testing
or for application in regenerative medicine strategies [45,105]. The main categories of ECT
constructs are depicted in Figure 1, with representative publications listed in Table 1 and
described below.
3.1. Cell Sheets
The cell sheet technique was first reported by Shimizu et al. in 2002 for creating
a transplantable 3D cell patch [57]. Cell sheet technology, also referred to as scaffold-
free system or “Cell Sheet Engineering” [57,106,107], is based on stacking monolayers (or
sheets) of CMs cultured to confluency to form 3D tissue-like structures. By using cell culture
surfaces coated with the temperature-responsive polymer poly(N-isopropylacrylamide)
(PIPAAm), it is possible to readily detach intact cellular monolayers of CMs as cell sheets
by lowering the temperature, without any enzymatic treatments. Overlaying these thin
2D monolayers then results in 3D cardiac constructs [108]. The benefits of this system
have been analyzed in vivo in murine animal models of MI showing improvements in cell
survival, cardiac function and tissue remodeling [109]. The use of cell sheets created new
opportunities for in vitro tissue engineering and helped exploring new therapies and drugs
for heart diseases [58,59]. Interestingly, Sekine et al. produced in vitro vascularized cardiac
tissues with perfusable blood vessels by overlaying additional triple-layer cell sheets made
by NRCMs cocultured with endothelial cells. Such sheets were then transplanted under
the neck skin of nude rats and connected to the local vasculature. Constructs with vessel
anastomoses survived and maintained their vascular structure up to two weeks after
transplantation. However, the thickness of the constructs decreased over time indicating
that uniform perfusion was insufficient for whole tissue survival. Moreover, no functional
analyses were performed in the study to evaluate maturation at tissue level [58]. More
recently, Kawatou et al. developed an in vitro drug-induced Torsade de Pointes arrhythmia
model using 3D cardiac tissue sheets. Importantly, the authors showed the importance of
using multi-layered 3D structures containing a hiPSC-derived heterogeneous cell mixture
(CMs and non-myocytes) in order to recapitulate disease-related phenotypes in vitro [59].
In addition, phase II clinical trials have been performed by Japanese scientists to evaluate
the efficacy and safety of autologous skeletal myoblast sheet transplantation in patients with
advanced heart failure. They demonstrated that the transplantation of engineered tissue
promoted left ventricular remodeling, improved the heart failure symptoms and prevented
cardiac death with a 2 year follow-up period [110]. Also, the potential use of cell-sheets
that contain allogeneic hiPSC-CMs for clinical transplantation is under investigation [111].
A clear advantage of cell sheet technology for therapeutic applications is the absence of
biomaterials, which reduces the risk of immune rejection that could arise from xenobiotic or
non-autologous materials, and that no suture is needed to ligate the construct to the injured
heart. Moreover, sheet technology enables direct cell-to-cell communications between
cells in the transplanted sheets and the host tissue, facilitating electrical communication
and vascular network formation within the cell sheet structure. On the downside, it has
been argued that the fragility of these sheets makes them difficult to manipulate during
implantation onto the heart [112]. Although cardiac tissue sheets have many advantages
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over other tissue engineering methods, these structures are not thick enough to reproduce
the high complexity of the native myocardial tissue.
3.2. Scaffolds
ECT constructs made by repopulating cell-free scaffolds with suitable cells are usually
referred to as cardiac patches. Scaffolds for CTE usually consist on a 3D polymeric porous
structure that contributes to cell attachment and leads to the desirable cell interaction
for further tissue formation [11,23,25–27,69,113–115]. Many different materials have been
tested for the fabrication of scaffolds suitable for CTE, including natural and synthetic
biomaterials. A commonly used synthetic material is polylactic acid (PLA), which is
easily degradable forming lactic acid. PLA scaffolds were tested in some cardiovascular
studies [116,117]. Another example is polyglycolic acid (PGA) and its copolymer with
PLA poly(D,L-lactic-co-glycolic acid) (PLGA), an FDA approved biomaterial among the
first tested for CTE due to its high porosity, biodegradability and processability [69,70,118].
However, it has been noted that the high stiffness of PLGA may limit the capacity of CMs to
remodel the scaffold and ultimately impinge on their maturation [112]. Collagen, being the
most abundant protein in the cardiac extracellular matrix (ECM), has a fibrillar structure
that facilitates CM scaffolding. In addition to good biocompatibility, biodegradability
and permeability, collagen also elicits low immunogenicity and can be engineered in
various formats including high porosity scaffolds, all of which make of collagen the
most commonly used biomaterial in scaffold-based CTE [21–25,28,119]. Other natural
biomaterials used in this context include alginate, a polysaccharide derived from algae
used in ECT constructs [26,120] due its high biocompatibility and appropriate chemical
and mechanical properties [121], and albumin fibers, which have been used to create
biocompatible scaffolds of high porosity and elasticity [29,122].
The combination of different approaches has enabled the development of scaffold
systems of increasing complexity, thus bringing them morphologically closer to heart tissue.
For example, researchers have generated fibrous scaffold with spatially distributed cues that
enabled CM alignment within the patch [29,123,124]. However, major limitations of CTE
still remain the generation of thick constructs (over ~100 µm in thickness) and the lack of
electromechanical coupling between the cardiac patch and the host myocardium [100,112].
The generation of ECT constructs with a clinically relevant size requires ensuring that
appropriate levels of oxygen and nutrients are maintained within the construct to satisfy
the metabolic demand of CMs. Perfusion bioreactor systems pioneered by the Vunjak-
Novakovic laboratory have proven to be of great value for the generation of thick ECT
constructs full of viable cells with aerobic metabolism. In this case, cells were seeded
and cultured in porous collagen scaffolds (11 mm in diameter, 1.5 mm in thickness) under
continuous perfusion for 7 to 14 days, which led to the formation of contractile thick cardiac
tissues [113,125]. More complex bioreactor systems designed to perfuse ECT constructs
while also delivering electrical signals mimicking those in the native heart have also been
developed [26,27,32]. Maidhof et al. used NRCMs seeded under perfusion into porous
poly(glycerol sebacate) (PGS) scaffolds (8 mm in diameter, 1 mm in thickness), which
were maintained under continuous perfusion at a flow rate of 18 µL/min and electrically
stimulated at a frequency of 3 Hz. After 8 days, the combination of perfusion and electrical
stimulation resulted in cell elongation, structural organization and improved contractility
of ECT constructs [27]. Recently, our laboratories have reported the generation of 3D engi-
neered thick human cardiac macrotissues (CardioSlices). Human iPSC-CMs were seeded
together with human FBs into large 3D porous collagen/elastin scaffolds and cultured
under perfusion and electrical stimulation in a custom-made bioreactor. Two weeks after
culture, stimulated ECT constructs exhibited contractile and electrophysiological properties
close to those of working human myocardium [32].
In addition to scaffolds made from synthetic or natural biomaterials, the use of matri-
ces obtained by decellularizing native tissues has gained popularity for CTE. The process of
decellularization allows obtaining natural ECM that can be used to mimic the native tissue
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structure. In essence, decellularized ECM could be recellularized with CMs or mixtures
of CMs and other cell types, or with PSCs that would be differentiated in situ toward the
desired cell types [126]. Tissues from a wide variety of sources including human, animals
and plants have been used for this purpose [112]. The porcine heart is a prime example
of tissue source for animal-derived decellularized scaffolds, due to its large size and to
it being a preferred experimental model for cardiovascular research. In this case, it has
been reported that the decellularization procedure allows obtaining a cardiac scaffold with
preserved vasculature, mechanical integrity and biocompatibility [127]. Nevertheless, limi-
tations noted with this approach include the extent of preservation of the ECM composition
(which can be altered by the decellularization process), the difficulty in recellularizing the
scaffold with clinically relevant numbers of CMs (in the order of billions), and the risk
of eliciting immune rejection [112]. The issue of immune intolerance of animal-derived
decellularized scaffolds has prompted research on plant-derived biomaterials as a source
for ECT constructs [128]. Even though promising results have been reported using bio-
materials derived from decellularized apple [129,130], spinach and parsley leaves [131],
along with other cellulose-based scaffolds [132,133], further evaluation will be necessary
to assess the usefulness of this type of materials for in vitro bioengineering and in vivo
therapeutic applications.
Alternatively, human tissue might be a more appropriate source for decellularized
ECM for therapeutic purposes, as it would address some of the limitations of animal-
and/or plant-sourced materials described above [134–137]. In this respect, studies by
Sanchez et al. demonstrated that the human acellular heart matrix can serve as a biocom-
patible scaffold for recellularization with parenchymal and vascular cells [138]. Moreover,
Guyete et al. also used human decellularized heart tissue, which was in this case re-
cellularized with iPSC-CMs and maintained in a custom-made bioreactor that provided
coronary perfusion and mechanical stimulation. After 14 days in culture, the recellularized
cardiac segment presented high metabolic activity and contractile function but exhibited
low maturation state [139].
3.3. Hydrogels
Embedding suitable cells in hydrogels provide important 3D information cues and, in
the context of CTE, the constructs generated in manner are typically known as cardiac grafts.
Hydrogels are among the most widely studied types of biomaterials in CTE (see Table 1).
In particular, hydrogel-based materials have been shown to provide structural/mechanical
support to cells [140], promote vascularization [141] and cell migration, differentiation
and proliferation [142], and to improve cardiac function after implantation in murine and
porcine models of MI [30,45,103]. Hydrogels can be made from different biomaterials that
are usually classified into three types: natural (type I collagen, fibrin, gelatin, alginate,
keratin, among other), synthetic [polycaprolactone (PCL), polyethylene-glycol (PEG), PLA,
PGA and their co-polymer PLGA], and hybrid hydrogels, which are made by combining
natural and synthetic polymers [143,144]. Natural-based hydrogels are often preferred
for generating ECT constructs because of their high bioactivity, biocompatibility and
biodegradability [142].
Cardiac “bundles” are the most common structures generated when using hydrogel-
based systems and are cylindrical ECT constructs in the form of cables, ribbons or rings [112].
These structures are usually formed by embedding CMs from various sources within hy-
drogels made up of fibrin, type I collagen or other biomaterials, and maintaining them
in culture until constructs become spontaneously contractile. The formation of these
bundles results in self-alignment and anisotropic organization of CMs, which is a hall-
mark of cell maturation. Moreover, these constructs provide an easy way to analyze
the electrical and mechanical properties of CMs, thus enabling the readily evaluation of
their maturation state and facilitating their use in drug screening and toxicity assessment
platforms [16,36,40,48,50,51,55,145–147].
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In a pioneering approach, Eschenhagen and Zimmermann generated cardiac bundles
(which they termed engineered heart tissues, or EHTs) by casting a mixture of NRCMs and
a blend of type I collagen type I and Matrigel into cylindrical molds. Under conditions of
mechanical stretching, the resulting ring-shaped constructs exhibited improved contractile
function and a high degree of cardiac myocyte differentiation [33]. In subsequent work,
five of such rings were stacked on a custom-made structure creating multiloop tissue
constructs that survived after implantation and improved the cardiac function of infarcted
rats [103]. Using the same principle, Kensah et al. produced cardiac bundles by seeding
NRCMs with FBs in a collagen/Matrigel hydrogel into a Teflon casting mold between two
titanium rods and subjected to mechanical and/or chemical stimulation [34]. Similarly,
human ECT constructs have also been generated by casting a cell/hydrogel suspension in
different types of molds between or around flexible posts. Schaaf et al. used hESC-CMs
in a fibrin hydrogel seeded into an agarose casting mold between 2 elastic silicone posts
for 5 weeks [37]. Controlling the 3D microenvironment has been further reported to in-
duce spatial organization and promote CM maturation in hydrogel-based systems. In a
study by Thavandiran et al., hESC-CMs and hESC-derived cardiac FBs were seeded in
a collagen/Matrigel hydrogel into polydimethylsiloxane (PDMS) microwells with inte-
grated posts. The authors compared two-well designs side by side: an elongated microwell
containing posts in both extremes (capable of inducing uniaxial mechanical stress) and
a square well containing posts around the edges (thus effecting biaxial mechanical con-
ditioning). These studies demonstrated that constructs on elongated microwells showed
comparatively better aligned sarcomeres and more elongated and longitudinally oriented
CMs [38]. In turn, the Bursac laboratory created thin (~70 µm in thickness) 3D sheet-like
constructs of large surface dimensions (7 × 7 mm) by casting hESC-derived CMs in fibrin
hydrogels into PDMS molds with hexagonal posts, resulting in improved maturation at the
functional (conduction velocities of up to 25 cm/s and contractile forces and stresses of 3.0
mN and 11.8 mN/mm2, respectively) and structural (increased sarcomeric organization
and expression of cardiac genes) level [100]. Similarly, Turnbull et al. generated human ECT
constructs with hESC-derived cells mixed in a collagen/Matrigel hydrogel in rectangular
PDMS casting molds with integrated posts at each end and removable inserts. Forty-eight
hours after casting, the inserts were removed from the mold, allowing the self-assembly
of the tissues between the two flexible posts, which were used as force sensors. The re-
sulting tissues exhibited typical features of human newborn myocardium tissue including
contractile, structural and molecular characteristics [42].
Similar to hESC-CMs, iPSC-CMs also have been successfully cultured in hydrogel-
based structures [11,40,46,47,49–51,53,55] (see Table 1). The Radisic laboratory pioneered
the use of hiPSC-CMs to generate human ECT constructs by developing a platform in
which cells in a collagen hydrogel organized around a surgical suture in a PDMS channel.
The resulting 3D microstructures (3 mm2) were termed Biowires and contained aligned
CMs that exhibited well-developed striations and showed improved cardiac tissue function
after electrical stimulation [40]. A further improvement to this platform was the use of
a polytetrafluoroethylene tube that allowed perfusion of the ECT microstructures and
facilitated their use for drug toxicity testing [41]. More importantly, three independent
studies reported in 2017 on the generation of clinical-size cardiac tissues by using hydrogel-
based systems and hiPSC-CMs. Shadrin et al. generated human cardiac tissues of 36 ×
36 mm that showed electromechanical properties close to those of working myocardium
(conduction velocity of 30 cm/s and specific forces of 20 mN/mm2) by seeding hiPSC-CMs
in a fibrin hydrogel into square PDMS molds [11]. Using a mixture of type I collagen
and Matrigel with hiPSC-derived CMs and endothelial and vascular cells (in a 3:1:1 ratio),
Nakane et al. generated rectangular ECT constructs with different shapes (bundles and
mesh junctions, parallel bundles, plain sheets) and sizes (from 15 × 15 mm to 30 × 30 mm).
They analyzed the association of CM orientation and survival with construct architecture
and found that bundles and mesh junctions resulted in the highest myofiber alignment
and lowest percentage of dead cells. Moreover, functional integration was observed after
Int. J. Mol. Sci. 2021, 22, 1479 11 of 29
4 weeks of transplantation onto rat uninjured hearts [50]. Large ECT constructs (35 × 34
mm) were also generated in the Zimmermann laboratory by seeding hiPSC-CMs and FBs
in a collagen hydrogel on a 3D-printed construct holder with flexible poles in a hexagonal
casting mold [51]. In a further refinement of this approach, Gao et al. generated human
ECT constructs of 4 × 2 cm comprising hiPSC-derived CMs, SMCs, and ECs (3:1:1 ratio) in
a fibrin hydrogel and maintained them in culture on a rocking platform. After 7 days of
culture, the constructs showed improved electromechanical coupling, calcium-handling,
and force generation [53].
Synthetic hydrogels have received comparatively less attention for CTE than those
of natural origin. Ma et al. used PEG to create cardiac microchambers (100 to 300 µm in
height) that induced spatial organization of hESCs and hiPSCs and directed their cardiac
differentiation [43,44]. In addition, hybrid hydrogels have a great potential for CTE as they
can mimic biological properties of the ECM and, at the same time, be tuned to suit the
mechanical properties expected or desired for cardiac constructs [148]. Despite their great
potential, much research is still needed to ascertain the specific advantages that synthetic
and hybrid hydrogels may have over commonly used natural hydrogels in the context of
CTE. At any rate, irrespective of the type of hydrogel used, current 3D cardiac grafts are
constrained in maximum thickness by the ~300 µm limit of oxygen diffusion in passive
culture systems and, therefore, while ideal for miniature structures with some tissue-like
functionalities, they may not be suited for applications that require fully capturing the high
complexity of the native heart tissue structure.
3.4. Cardiac Spheroids (and ‘Organoids’)
Spheroids are scaffold-free 3D cell constructs that rely on cell aggregation or self-
organization and simulate aspects of the native cell microenvironment [149]. Cardiac
spheroids can be constructed with CMs [150,151] and also include other cardiac resident
cells such as FBs [152] or ECs [104]. Different percentages of various cell types have
been tested for the generation of cardiac spheroids [153,154]. Spheroid-based systems are
attractive to scientists for studying heterocellular interactions and drug effects because they
only need low cell numbers to be formed. On the other hand, the absence of functional
architecture limits the physiological analyses of the cells, like force generation and electrical
conduction. Nevertheless, using the spheroid-based systems to deliver CMs into the
damaged region of the heart has been reported. For instance, intramyocardial injection
of cardiac spheroids in mice resulted in higher engraftment rates and improved electrical
coupling with host myocardium, compared to single cell injection, which reveals potential
for future clinical applications [155,156]. Moreover, several research groups are working
on the generation of thicker functional structures using multicellular spheroids for further
clinical testing. Noguchi et al. created a scaffold-free 3D tissue construct based on self-
organization of 1 × 104 spheroids. The individual spheroids were, in turn, obtained by
combining 3 cell sources: NRCMs, hECs and hFBs in a 7:1.5: 1.5 ratio. ECT constructs
generated in this way remained adherent and presented signs of vascularization seven
days after transplantation onto the heart of nude rats [157]. In a related approach, scientists
created a biomaterial-free cardiac tissue by 3D printing multicellular cardiac spheroids
that displayed spontaneous beating and ventricular-like action potentials, which were
engrafted as well into the rat heart tissue [158]. A final example of this approach is the
study by Kim et al., who generated elongated 3D heterocellular microtissues by fusing
together multicellular cardiac spheroids containing CMs and cardiac FBs. The authors
demonstrated that such microtissues formed an electrical syncytium after seven hours in
culture [159].
Similar to spheroids, organoids are scaffold-free 3D cell constructs that simulate as-
pects of the native environmental conditions. However, a critically important characteristic
of organoids that sets them apart from spheroids, is that organoids contain organ-specific
cell types that self-organize in a way that is architecturally similar to that of the native
organ [160]. While some researchers may use the terms organoids and spheroids inter-
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changeably, there are important differences between them. Both spheroids and organoids
can be generated from PSCs, PSC derivatives, or tissue-specific stem/progenitor cells.
When using PSCs, the technique of organoid formation is inspired in the embryoid body
system [160], 3D aggregates of PSCs where cells undergo specification and differentiation
into cell derivatives of the three main embryo germ layers [161]. In contrast, spheroids
are much simpler than organoids in terms of the cell types that conform them, do not
self-organize into organ-like patterns or structures, and depend to a lesser extent on ECM
properties and composition [162]. Even though several published reports describe the gen-
eration of human “cardiac organoids”, these rely on direct cardiac differentiation of hiPSC-
derived embryoid bodies [163] or aggregation of cardiac cell types (CMs, cardiac FBs and
cardiac ECs) [164–168], which actually represent typical examples of spheroids [160,161].
We believe that the use of the term “cardiac organoids” in this context is misleading since
the structures generated in those studies lacked the organ-like complexity characteristic
of true organoids. Very recently, Lee et al. have described the generation of bona fide
cardiac organoids in the mouse system that showed atrium- and ventricular-like structures
highly reminiscent of the native embryonic heart. For this purpose, the authors induced
sequential morphological changes in PSC-derived cells by including a laminin-entactin
complex in the ECM and FGF-4 in serum-free medium [169]. Perhaps the application of
similar approaches to hiPSC derivatives could lead to the generation of true human cardiac
organoids containing relevant organ-specific cell types with the capacity to self-organize in
organ-like structures.
3.5. Heart-on-a-Chip
Microfluidic cell culture technologies enable researchers to create in vitro cell mi-
croenvironments that mimic organ-level physiology [170]. The term ‘organ-on-a-chip’ is
generally applied to a microphysiological system, including the slides or plates that are
connected to microfluidic devices to control perfusion of culture medium and exposure
of defined stimuli [171]. Heart-on-a-chip technology refers specifically to microphysio-
logical systems mimicking the function of heart tissue. In vivo-like cardiac cell culture
systems could lead to a better understanding of (1) cardiac cell physiology; (2) cardiotoxic-
ity of drugs intended for human used; (3) personalized treatments for CVD patients; and
(3) mechanisms of heart regeneration [39,172,173]. In physiological conditions, the heart
tissue is in direct contact with body fluids such as blood and lymph that exert physical
forces (shear stress) on the cells. This continuous flow stimulation determines the cardiac
cells structure, phenotype, intra- and extracellular interactions [174]. In vivo-like cardiac
cell culture systems try to replicate these conditions in vitro. Thus, the heart-on-a-chip
system provides suitable conditions to imitate biochemical, mechanical, and physical sig-
nals characteristic of heart tissue [175–177]. For example, it was shown that continuous
perfusion enhances cell proliferation and parallel alignment of cells compared to static
conditions [178]. In addition to perfusion, integrating mechanical and electrical stimulation
into heart-on-a-chip devices also improves the maturation state of CMs [54,179–181], one
of the key features for successful modeling of cardiac diseases [182]. Moreover, heart-on-
a-chip systems are amenable to parallelization and thus to be used in high-throughput
assays for drug screening and cardiotoxicity testing [173,183]. Particularly, the possibil-
ity of using hPSC-CMs brings an additional level of personalization to heart-on-a-chip
systems [46,54,104,184–187]. For example, the Radisic laboratory developed a powerful
platform, dubbed AngioChip, that integrated tissue engineering and organ-on-a-chip tech-
nologies to produce vascularized polymer-based microfluidic cardiac scaffolds. Such a
platform can be used to generate both in vitro heart tissue models and in vivo implants for
potential clinical application [186].
3.6. 3D Bioprinting
3D bioprinting is one of the latest additions to the tissue engineering toolbox, and
one that could be used to create complex and large vascularized tissues [188,189]. Several
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methods of 3D bioprinting have been used in the context of CTE, including cell-laden
hydrogel 3D structures [190], inkjet bioprinting [191], laser-assisted bioprinting [192], and
extrusion-based bioprinting [193]. Biomaterials used in 3D bioprinting are based on piezo-
resistive, high-conductance, and biocompatible soft materials. Gaetani et al. bioprinted a
2 × 2 cm ECT construct using human cardiac progenitor cells and alginate matrices, which
was maintained for 2 weeks in vitro [120] or transplanted onto rat infarcted hearts where it
led to cell engraftment [194]. Generation of 3D-bioprinted vascularized heart tissues using
mouse iPSC-CMs with human ECs in a PEG/fibrin hydrogel has been recently reported
showing improved connectivity to the host vasculature after subcutaneous transplantation
in mice [195]. Despite the early stage of development, 3D bioprinting is a very promising
technology for recapitulating the complex structure of heart tissue and already shows
enormous potential in CTE. In a recent study, Noor et al. succeeded in bioprinting thick
(2 mm) 3D vascularized and perfused ECT constructs that had high cell viability using an
extrusion-based bioprinter. As bioinks, the authors used an ECM-based hydrogel derived
from human decellularized omentum containing hiPSC-CMs, and gelatin containing iPSC-
derived ECs and FBs. Computerized tomography of a patient’s heart was used to reproduce
in vitro the structure and orientation of the blood vessels into the tissue. Bioprinted ECT
constructs were transplanted into the omentum of rats and analyzed after seven days,
when elongated and well-aligned CMs with massive striations were observed [56]. This
study demonstrated that the possibility of using fully personalized materials makes 3D
bioprinting technology very promising for clinical application by reducing the risk of
immune rejection after transplantation. However, the system is still limited and further
analyses should be performed to evaluate if heart tissue bioprinted in this manner could
sustain normal blood pressure levels after transplantation [56].
3D bioprinting can also be combined with microfluidic systems to provide superior
organ-level response with greater prediction of drug-induced capability [196]. On the
other hand, recent advances in nanomaterial technology present an attractive platform for
the creation of ECT constructs for biomedical applications. Electrospinning technology
allows creating nanofibers with controlled dimensions and further development of 3D
structures [197]. In addition, the nanofibrous structure provides appropriate conditions for
pluripotent cells to anchor, migrate and differentiate [198]. Increasing attention is being
given to these types of structures due to their distinct mechanical properties, high porosity
and potential to induce formation of aligned tissues that can be successfully implanted to
the heart [199].
3.7. Other Structures
So far, we have described the variety of approaches undertaken for the generation
of ECT constructs that reproduce increasingly complex features of the human myocardial
tissue. However, several groups have pursued approaches intended to model whole
heart chambers. In an early attempt in 2007, scientists created a “pouch-like” single
ventricle using a mixture of hydrogel composed of type I collagen and Matrigel and
NRCMs, which was cultured in an agarose casting mold with the dimensions of a rat
ventricle. After formation, it was transplanted onto the rat heart showing limited functional
integration [200]. One year later, Lee et al. created a “cardiac organoid chamber” by seeding
NRCMs mixed with a collagen/Matrigel hydrogel around a balloon-like shaped mold
with a thickness of 0.65 mm and sizes of 4.5 to 9 mm for the unloaded outer diameter,
equivalent to the sizes of embryonic rat hearts at 9.5–11 days of development. The authors
succeeded in the creation of a heart ventricle but with a moderate contractile capacity [201].
In subsequent work, the same group used a similar method to produce a functional human
cardiac chamber using hESC-CMs embedded in collagen-based hydrogel. They proved
that such technology could facilitate drug discovery as it provides the capacity to measure
clinically meaningful parameters of the heart like ejection fraction and developed pressure,
as well as electrophysiological properties [202]. The Parker laboratory has also recently
generated tissue-engineered ventricles by using nanofibrous scaffolds composed of PCL
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and gelatin seeded with either NRCMs or hiPSC-CMs on a rotating ellipsoidal collector. The
authors showed that cells aligned following the fiber orientation, thus recapitulating the
orientation of the native myocardium, although the contractile function was much smaller
than those of the native rat/human ventricles most likely owing to the small thickness of
the chamber [203]. Notably, the Feinberg group printed human cardiac ventricles in 2019
using the freeform embedding of suspended hydrogels (FRESH) method. In this case, type
I collagen was used as a support material to create an ellipsoidal shell that was filled with
hESC-CMs in a fibrinogen suspension. These engineered tissues displayed synchronized
functional activity [204]. Finally, Kupfer et al. have very recently generated a 3D bioprinted
chambered muscle pump using an optimized bioink formulation of ECM proteins that
allowed hiPSC proliferation prior to differentiation. In this way, 3D bioprinted hiPSCs
underwent cell expansion and differentiated into CMs in situ, yielding contiguous muscle
walls of up to 500 µm in thickness. The resulting human chambered organoids showed
macroscale contractions and continuous action potential propagation and were responsive
to drugs and to external pacing [205].
4. Maturation of Engineered Cardiac Tissues
Regardless of the cell source or type chosen, biomaterial used, or method employed
to generate ECT constructs, a critical aspect common to all of them is the requirement to
promote or maintain the maturation state of CMs in culture. The application of biophysical
stimuli mimicking those experienced by CMs in the native heart has been investigated in
greatest detail and found to be among the most efficient ways to obtain highly mature ECT
constructs. Thus, a variety of existing CTE technologies have incorporated the means to
apply relevant biophysical stimuli during culture to promote cellular growth, orientation
and/or maturation, and are reviewed below and summarized in Figures 1 and 2.
4.1. Mechanical Stimulation
Mechanical cues are among the most important stimuli during heart development,
ultimately determining the overall size and architecture of the organ, as well as regu-
lating physiological postnatal changes in the heart resulting from the growth process,
pregnancy, sports or injury [206]. Building on this notion, early studies investigated the
importance of mechanical stimulation for CM maturation using embryonic chick cells [207]
and NRCMs [60] embedded in collagen gels that were subjected to cyclic stretching. In
later work, Zimmermann et al. used linear cyclic stretching to generate ECT constructs
that exhibited contractile and electrophysiological properties similar to those of the rat
native tissue. Specifically, the authors used circular molds to cast collagen-based con-
structs that, after 7 days in culture, were transferred to a device applying circular cyclic
stretching. Transplantation of the constructs generated in this way to the healthy rat heart
showed its fast integration and the high percentage of terminal cardiac differentiation
achieved [33]. The positive role of mechanical stimulation for CM maturation was also
reported by Kensah et al. [34]. In this case, cyclic mechanical stretching together with
electrical stimulation of NRCMs resulted in improved maturation at the cell and tissue lev-
els, which was proved by the increased cardiac gene expression and improved functional
properties of the construct [34]. Similar results were obtained in another study where ECT
constructs were subjected to mechanical compression and to the shear stress induced by
medium perfusion in a bioreactor system. Additionally, elevated levels of bFGF and TGF-β
and higher expression of Cx43 were observed under intermittent compression, which
suggested improvement in cell-cell communication [28]. Moreover, combining mechanical
stimulation with other strategies such as co-culturing CMs with ECs [36] or using highly
defined media based on specific growth factors (FGF-2, IGF-1, TGF-β1, VEGF) [51] fur-
ther increased the structural and functional maturation of ECT constructs derived from
hESC and hiPSC [31,36,51]. Overall, the application of mechanical stimulation improves
sarcomere organization, cardiomyocyte contractility, increases tensile stiffness and cell size.
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On the other hand, the application of mechanical stimulation alone may not be enough
for obtaining mature cardiac tissues. During heart development, CMs experience mechan-
ical forces and electrical fields resulting from the synchronized contraction of the organ
itself, which greatly influence their further differentiation and maturation [208,209]. For
this reason, recent CTE studies used the combination of these two stimuli [35,38]. For
example, Ruan et al. compared the influence of mechanical stimulation on the maturation
of cardiac constructs alone or in combination with electrical stimulation. The authors
created hiPSC-derived collagen-based 3D scaffolds that either underwent static stress
conditioning for 2 weeks or were subjected to mechanical stimulation for one week fol-
lowed by a second week with additional electrical stimulation. They demonstrated that,
in response to mechanical loading alone, the engineered tissue showed increase in CM
alignment and size, and improved contractility, force generation and passive stiffness of
the constructs. The addition of electrical stimulation further improved force generation
and increased expression of Ca-handling proteins but without further changes in cell size
and alignment [47].




Figure 2. General features of cardiac maturation at the cellular and tissue levels. Cardiac matura-
tion at the level of cardiomyocytes (blue-shaded background) can be experimentally ascertained 
by a more adult-like cardiac gene expression profile, changes in sarcomeric ultrastructure result-
ing in sarcomere elongation and alignment, increased mitochondrial density to accommodate for 
higher energy demand, and massive growth in cardiomyocyte size (hypertrophy) with increased 
percentage of polyploid cells. Electrophysiologically, cardiomyocyte maturation results in a more 
negative resting membrane potential and increased duration and amplitude of action potential. 
Cardiac maturation at the tissue level (pink-shaded background) is characterized by elongated 
cardiomyocytes preferentially aligned along a specific axis, increased expression of Cx43 and dis-
tinct localization of gap junction proteins, and improvements in impulse propagation and syn-
chronization of cardiac contraction, leading to cardiomyocytes performing as a functional syncyt-
ium. Maturation at the tissue level results in increased contractility and force generation and, elec-
trophysiologically can be registered as compound action potentials reminiscent of surface ECG 
recordings. Figure created with BioRender.com and smart.servier.com. 
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4.2. Electrical Stimulation
Electromechanical coupling is one of the major characteristics of mature CMs resulting
in their synchronous response to the elect ical pacing signals following with contractile
function and pumping. The process of cardiac muscle co tr cti is generated by the
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depolarization of the CM membrane, which in the end leads to calcium release from
the sarcoplasmic reticulum and subsequent contraction of the myofibrils [210]. Thus,
researchers began to test the effects of electrical stimulation to train cardiac constructs.
The Vunjak-Novakovic laboratory pioneered the application of electrical stimulation to
ECT constructs by culturing NRCMs on thick collagen sponges and subjecting them to
electrical pulses at 1 Hz for up to 8 days. They observed that electrical field stimulation
induced cell alignment and improved ultrastructure organization along with an increase in
the amplitude of synchronous contractions, whereas non-stimulated constructs displayed
poorly developed ultrastructural features [23]. For the purpose of electrical stimulation,
the group initially developed a simple electrical stimulation chamber with two carbon rod
electrodes placed lengthwise along the bottom of a Petri dish that also allowed to evaluate
the functional properties of the constructs [25]. In further refinements, more complex
systems were developed that better mimicked conditions in the native heart, including a
bioreactor system that allowed simultaneous perfusion and electrical stimulation of the ECT
constructs [27]. The benefits of this combined system were highlighted by the presence of
elongated CMs with marked striations, a well-defined intracellular structure, high levels of
expression and proper localization Cx43, and increased conduction velocity and enhanced
contractility of the construct. The combination of perfusion and continuous electrical
stimulation has been extensively used by other research groups to promote functional
maturity. For instance, Barash et al. integrated custom-made stimulating electrodes in
a bioreactor system to electrically stimulate thick rat ECT constructs under perfusion.
After 4 days in culture in this system, the constructs showed enhanced levels of Cx43
and improved cell striation and elongation [26]. In another study, Xiao et al. designed a
microfabricated bioreactor with integrated electrodes to engineer mature rat microtissues
for assessing in vitro pharmacological effects [41].
The positive effect of electric stimulation on CM maturation has been validated for
human cells using hESC- and hiPSC-derived ECT constructs. Nunes et al. were the first
to use a daily step-up protocol to test the effect of increasing stimulation frequency on
human 3D self-assembled cardiac bundles (Biowires). Specifically, ramping up stimulation
frequency over a 1-week period enhanced maturation, with a 1 to 6 Hz paradigm resulting
in better results than a 1 to 3 Hz, as judged by improved sarcomeric organization, increased
number of desmosomes and subsequent higher conduction velocities, and overall more
mature Ca-handling and electrophysiological properties [40]. More recently, Ronaldson-
Bouchard et al. generated ECT constructs of early-stage hiPSC-CMs (immediately after
the initiation of spontaneous contraction) in fibrin hydrogels and maintained them in
culture for one month while increasing the frequency of electric stimulation from 2 Hz
to 6 Hz at a rate of 0.33 Hz per day. Tissues cultured under these conditions displayed
a remarkably advanced state of maturation including adult-like cardiac gene expression
and tissue ultrastructure, a positive force-frequency relationship, and functional calcium
handling [55].
While the effects of electric stimulation have been analyzed in detail on the maturation
of human ECT microconstructs and of perfused rat macroconstructs, perfusion bioreac-
tors incorporating electrical stimulation have been more rarely employed to generate
human ECT macroconstructs [43,51,52]. Indeed, only recently have hiPSC-derived cells
and 3D thick scaffolds been combined with continuous electrical stimulation to develop
macrotissues of human CMs. For this purpose, the group of one the authors developed
a parallelized perfusion bioreactor with custom-made culture chambers endowed with
electrostimulation capabilities. We showed that hiPSC-CMs readily survive and mature
after long-term culture within large (10 mm in diameter by 2 mm in thickness) 3D porous
scaffolds, giving rise to macroscopically contractile tissues, which we termed ‘CardioSlices’.
More importantly, we found that continuous electrical stimulation of these large ECT
constructs for 2 weeks promoted the alignment and synchronization of CMs, and the
emergence of complex cardiac tissue-like behaviors, including the spontaneous generation
of electrophysiological signals strikingly similar to human electrocardiograms, which could
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be readily registered from the construct surface, and a response to proarrhythmic drugs
that was predictive of their effect in humans [32].
4.3. Coculture with Non-CMs
Since cardiac cells other than CMs play important roles in heart homeostasis, several
groups have explored whether their incorporation into ECT constructs improved cardiac
maturation. Indeed, epicardial cells closely interact with CMs and regulate myocardial
wall development [211] and, through paracrine mechanisms, influence heart electrophysi-
ology [212,213]. Cardiac endocardial cells are found in direct contact with CMs, supporting
their metabolic activity and regulating their contractility via paracrine signals [214]. Studies
on neonatal and fetal CMs have shown that inclusion of cardiac FBs and/or ECs into ECT
constructs improved the morphological and functional maturation of CMs [113,215,216].
Thavandiran et al. directly tested whether the cell composition of ECT constructs affected
their functionality. For this purpose, the authors incorporated ESC-derived CMs and CFs
in different ratios into collagen based microtissues, and found that the 3:1 (CMs:CFs) ratio
provided the best microenvironment based on increased expression of cardiac maturation
genes [38]. Similarly, Gao et al. generated a clinical size human ECT construct using
hiPSC-CMs, -ECs and -SMC (2:1:1) in a fibrin hydrogel and reported a significant functional
maturation of the construct in vitro and high engraftment rates in vivo [53]. Thus, the
combination of more than one cell type within the ECT constructs can also aid in promoting
their morphological and functional maturation [36,51,58,59].
5. Functional Assessment of Engineered Cardiac Constructs
The development of CTE approaches to increase the cardiac maturity of ECT constructs
is necessarily mirrored by advances in the methodologies used to evaluate their degree
of maturation. As described in the previous sections, the vast majority of human ECT
constructs developed to date are hydrogel-based and do achieve measurable increases in
CM maturation when analyzed at the cellular level, both in miniature constructs and thin
sheets. Specific improvements in CM maturation were most frequently analyzed in terms
of gene/protein expression profile, sarcomeric structure and/or cell electrophysiological
properties being closer to those of adult CMs. Some studies also analyzed functional tissue-
like properties of the engineered constructs, such as force generation and contractility, and
a few studies also measured propagation of the electrical signals by analyzing calcium
transients or voltage-sensitive dyes (see Table 1). The advantages and limitations of the
technologies used to assess the functional maturation of ECT constructs are summarized in
Table 2 and discussed below.
Table 2. Main approaches to functional assessment of ECT constructs.
Approach Advantages Disadvantages Ref.
Patch-clamp
- Direct recording of action potentials
- Ideal for recording isolated CMs
- Requires specialized
equipment/personnel
- Requires direct cell visualization
- Not well suited for ECT constructs
[217]
Multielectrode arrays
- Allows assessment of single CMs
and ECT constructs
- Noninvasive method.
- Allows long-term recording
- Measurements restricted to small
area of the ECT construct.




- Allows assessment of CM
monolayers and ECT constructs
- Noninvasive method
- Unsophisticated equipment
- Indirect measurement of
electrophysiological parameters





- Allows assessment of single CMs
and ECT constructs
- Allows measuring direct and
indirect contractile force
- Allows long-term measurements
- Unsuitable for assessing contractile
stress from single CMs within
ECT constructs
[36,39,42,47,48,50,57,217]
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5.1. Patch-Clamp and Microelectrodes
Patch-clamp is the gold standard technique used to study the electrophysiological
properties of excitable single cells such as PSC-CMs [37,40,49,51,55]. This technique allows
measuring transmembrane voltage and currents using pulled glass micropipettes [222]).
In addition, electrical coupling between two cells can be measured by applying patch
electrodes to each of them separately [223]. Changes in membrane potential like action
potentials can be measured by a whole-cell current clamp or using sharp microelectrodes
with narrow bores [33,49,224], which allow precise registering of action potentials due to
preservation of the true intracellular milieu [217]. While ideal for recording isolated CMs,
patch-clamp technology presents important limitations for the study of ECT constructs.
In addition to the inherent low throughput of the technique and the need for specialized
equipment and highly trained personnel, patch-clamp requires direct visualization of the
cell(s) being analyzed, which is not straightforward when cells are inside an ECT construct.
Moreover, patch-clamp measures the electrophysiological properties of CMs themselves,
rather than those of the construct as a tissue.
Functional assays used to evaluate the cardiac maturation state of the constructs, both
at the cellular and the tissue levels, indicating the main advantages and disadvantages of
each approach, as well as references to publications where those approaches were used in
the context of CTE. CM, cardiomyocyte; ECT, engineered cardiac tissue.
5.2. Multielectrode Arrays
Multielectrode arrays (MEAs) are devices that contain arrays of electrodes distributed
over a small surface on which cells can be cultured directly. MEAs are generally used for
millimeter-scale analysis of extracellular potential within beating clusters of CMs [43,225],
where they can measure extracellular field potential, spontaneous beating rate, repolariza-
tion characteristics, and conduction velocity and trajectories [226]. Unlike patch-clamp,
MEA technology can be used to assess the electrophysiological properties of CMs at both
the single-cell and tissue levels in cell monolayers or ECT constructs [59,108,218], and
allows long-term recording of electrophysiological parameters noninvasively [219]. The
main limitations of MEA technology for the functional evaluation of ECT constructs are
that measurements are restricted to the small areas detected by the electrodes, and that it
provides incomplete information about the shape of the propagated action potentials [217].
5.3. Optical Mapping
Optical mapping is a non-invasive method for the assessment of electrical activity that
is well established for the study of cell monolayers [227] and has also been applied to ECT
constructs [29,35,40,48,55,99,118,220]. This technique relies on the use of voltage-sensitive
(di-4-ANEPPS, di-8-ANEPPS and RH237) [228] or Ca2+-sensitive fluorescent dyes (rhod-2
and fluo-4). The main advantage of this technique is the ability to monitor the electrical
activity and shape of action potentials from many areas of the construct. On the other hand,
these dyes have cytotoxic effects that limit the maximum duration of experiments [221].
Moreover, the dyes are light-sensitive and subject to photobleaching, further limiting the
time of analysis and reassessment of the sample. Optical mapping has been combined
with MEA technology for the study of conduction velocity, direction of the signal and
visualization of arrhythmias [229].
5.4. Force Transducers
The mechanical force exerted by contracting CMs can be measured in single cells
as well as in whole ECT constructs [36,42,47,48,50,57,100]. For single-cell measurement,
one end of the CM is attached to a rigid steel needle and the other end to a piezo-electric
motor for its stretching. Force measurements are then taken by a sensitive force transducer
connected to the needle [230]. For tissue-level properties, the whole construct is connected
to a force transducer [36,47,48,100]. Here, the main disadvantage is the inability to measure
the contractile stress from each CM. Advantages, on the other hand, include the larger
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magnitude of the signals obtained and the possibility to measure the therapeutic potential
of ECT constructs before implantation [217].
To date, those are the most complex multicellular (tissue-level) behaviors analyzed in
the context of CTE. New methods with greater sensitivity will be needed for evaluating
tissue-like functional properties. Recently, the group of one the authors has explored
the use of surface electrodes to record the electrical activity of thick ECT constructs. The
bioelectrical signal detected in this way was extremely informative of the activity of
electrically-active cells within the construct and, most importantly, of the intercellular
coupling at the macro (whole construct) scale, resulting in complex waves very reminiscent
of surface ECG recording in humans. In our study, we showed that electrical stimulation of
the constructs resulted in improvements in tissue-like properties (shape of ECG-like signals
and response to drugs) that could not be predicted by the small increases in maturation
achieved at the CM level [32].
6. Summary and Future Directions
One of the most pressing current challenges in CTE is how to achieve a level of
cardiac maturation that resembles that of the adult human myocardium. This is even
more important for experimental approaches based on PSC-CMs that, while clearly taking
the center stage of CTE, are notoriously difficult to mature ex vivo [182,231]. The use of
immature cells/constructs could lead to the improper interpretation of in vitro drug testing
results and inaccurate prediction of their effect in vivo upon transplantation. We have
reviewed here the variety of imaginative approaches researchers have employed to obtain
mature CET constructs using mechanical and/or electrical stimulation and coculture with
non-myocyte cells, as well as biochemical interventions. These approaches have proven
successful in promoting CM maturation from an embryonic-like state to cells displaying
late fetal phenotypes. We have also reviewed how transplantation of such CET constructs
had positive impact in cardiac function in experimental animal models and even patients.
However, it should be noted that, to our knowledge, no approach has yet succeeded in
obtaining CMs with maturity features beyond those of early postnatal CMs. Moreover,
much of the earlier work attempting to obtain adult-like cardiac constructs concentrated on
increasing the degree of maturation at the CM cell level, and had limited success in achiev-
ing functional tissue-like properties [40,47,51,55]. Taking into account that the myocardial
tissue is a complex system that requires the synchronized operation of CMs as a functional
syncytium [232], we contend that improving high-order behaviors at the macroscale (tissue)
level could lead to more adult-like phenotypes, even when the maturation state of indi-
vidual CMs were only marginally improved [32,47]. Future research will be necessary to
explore whether the synergistic exploitation of approaches improving cardiac maturation
at both the CM and the tissue levels will result in ECT constructs with the features of
adult human myocardium. Moreover, pending issues such as improving the functional
integration of ECT constructs within the host myocardium, increasing their durability and
scalability, along with making them amenable to cryopreservation, surely warrant further
research. Considering the multidisciplinary nature of CTE, further developments in the
field will require the coordinated efforts from researchers with diverse backgrounds.
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